A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects with Erythropoietic Protoporphyria

Project: Research project

Project Details

StatusFinished
Effective start/end date6/6/18 → 11/30/20

Funding

  • Mitsubishi Tanabe Pharma: $11,310.00